GleamWall
中文EN

BCLI BRAINSTORM CELL THERAPEUTICS INC.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1137883 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY6.4%
TTM EPS YoY38.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-914.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets1,568.1%
Debt / equity—
Current ratio0.03x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-584.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$523,000$963,000$762,000$852,000$899,000$1.12M$1.30M$1.72M
SG&A expense$1.09M$2.65M$1.28M$1.39M$1.15M$1.45M$1.78M$1.47M
Operating income-$1.61M-$3.61M-$2.05M-$2.24M-$2.05M-$2.57M-$3.09M-$3.19M
Net income-$1.73M-$3.85M-$2.13M-$2.43M-$2.11M-$2.90M-$2.86M-$2.97M
EBITDA-$1.59M-$3.57M-$2.01M-$2.20M-$2.00M-$2.52M-$3.04M-$3.14M
EPS (basic)-0.14-0.35-0.19—-0.19-0.34-0.45—
EPS (diluted)-0.14-0.35-0.19—-0.19-0.34-0.45—
Weighted avg. shares (diluted)11.98M11.03M11.03M—11.01M8.62M6.34M—
Balance sheet
Cash & equivalents$163,000$209,000$206,000$29,000$236,000$1.02M$1.83M$371,000
Current assets$453,000$316,000$184,000$307,000$508,000$1.51M$2.33M$385,000
PP&E, net$123,000$152,000$198,000$235,000$283,000$331,000$382,000$434,000
Total assets$840,000$788,000$755,000$1.02M$1.38M$2.57M$3.57M$1.83M
Current liabilities$13.17M$12.38M$11.76M$11.01M$9.02M$8.53M$10.90M$8.98M
Short-term debt$1.88M$1.26M$1.33M$967,000$101,000$101,000$1.20M$300,000
Total liabilities$13.17M$12.38M$11.76M$11.01M$9.07M$8.62M$11.03M$9.60M
Shareholders' equity-$12.33M-$11.60M-$11.01M-$9.98M-$7.69M-$6.06M-$7.46M-$7.76M
Shares outstanding14.26M11.03M11.03M11.03M11.03M10.12M7.91M6.14M
Cash flow statement
Operating cash flow-$704,000-$895,000-$1.32M-$740,000-$1.10M-$3.50M-$1.63M-$1.05M
Financing cash flow$843,000$898,000$1.25M$780,000$313,000$2.70M$3.09M$1.06M
Depreciation & amortization$29,000$46,000$37,000$48,000$48,000$51,000$52,000$53,000
Stock-based compensation$570,000$2.24M$133,000$143,000$157,000$503,000$717,000$208,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.